Based on the key indicators related to Catalyst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Catalyst Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in January. At this time, Catalyst Pharmaceuticals' Property Plant And Equipment Net is fairly stable compared to the past year. Retained Earnings is likely to rise to about 127.3 M in 2024, despite the fact that Net Debt is likely to grow to (127.4 M). Key indicators impacting Catalyst Pharmaceuticals' financial strength include:
Investors should never underestimate Catalyst Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Catalyst Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Catalyst Pharmaceuticals.
Net Income
74.98 Million
Catalyst
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Change To Liabilities
Total Cash From Financing Activities
Stock Based Compensation
Change To Account Receivables
Sale Purchase Of Stock
Change To Inventory
Change Receivables
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Investments
Change To Operating Activities
Total Assets
Total Stockholder Equity
Net Debt
Cash
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Retained Earnings
Accounts Payable
Non Current Assets Total
Common Stock Total Equity
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Non Currrent Assets Other
Other Current Assets
Net Receivables
Other Liab
Non Current Liabilities Total
Net Tangible Assets
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Inventory
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Short Long Term Debt Total
Current Deferred Revenue
Capital Lease Obligations
Short Term Debt
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Income Tax Expense
Depreciation And Amortization
Selling General Administrative
Total Other Income Expense Net
Total Revenue
Gross Profit
Cost Of Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Tax Provision
Net Interest Income
Reconciled Depreciation
Selling And Marketing Expenses
Probability Of Bankruptcy
Understanding current and past Catalyst Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Catalyst Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Catalyst Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Catalyst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalyst Pharmaceuticals. Check Catalyst Pharmaceuticals' Beneish M Score to see the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.
Catalyst Pharmaceuticals Stock Summary
Catalyst Pharmaceuticals competes with Day One, Terns Pharmaceuticals, X4 Pharmaceuticals, Inozyme Pharma, and Mereo BioPharma. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Catalyst Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Catalyst Pharmaceuticals. It measures of how well Catalyst is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Catalyst Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Catalyst had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Catalyst Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catalyst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catalyst Pharmaceuticals competition to find correlations between indicators driving Catalyst Pharmaceuticals's intrinsic value. More Info.
Catalyst Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.65 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Catalyst Pharmaceuticals is roughly 1.54 . At this time, Catalyst Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Catalyst Pharmaceuticals Systematic Risk
Catalyst Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Catalyst Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Catalyst Pharmaceuticals correlated with the market. If Beta is less than 0 Catalyst Pharmaceuticals generally moves in the opposite direction as compared to the market. If Catalyst Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Catalyst Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Catalyst Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Catalyst Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Catalyst Pharmaceuticals Thematic Clasifications
Catalyst Pharmaceuticals is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Catalyst Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Catalyst Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Catalyst Pharmaceuticals growth as a starting point in their analysis.
Catalyst Pharmaceuticals December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Catalyst Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Catalyst Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Catalyst Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Catalyst Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Catalyst Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.